PMID- 22967344
OWN - NLM
STAT- MEDLINE
DCOM- 20140417
LR  - 20120912
IS  - 0254-6450 (Print)
IS  - 0254-6450 (Linking)
VI  - 33
IP  - 8
DP  - 2012 Aug
TI  - [Improvement in blood glucose fluctuations of insulin-treated type 1 diabetic 
      patients with additional use of acarbose and assessed by continuous blood glucose 
      monitoring program].
PG  - 854-6
AB  - OBJECTIVE: To investigate the effect of combined use of insulin and acarbose on 
      glucose excursion in type 1 diabetic patients. METHODS: 120 cases were randomly 
      divided into control group and observation group. The control group received 
      preprandial ultra-short effect insulin and long-acting insulin before bedtime 
      while the observation group received acarbose 50 mg added to the medicine taken 
      by the control group. Continuous Glucose Monitoring System (CGMS) was used to 
      watch the blood glucose fluctuations. Data related to blood glucose level, 
      glucose excursions after meals and hypoglycemia at night were compared between 
      patients in the two groups. RESULTS: The average blood glucose (9.37 +/- 1.70) 
      mmol/L, the largest amplitude of glycemic excursions (LAGE) (11.42 +/- 2.73) 
      mmol/L, hyperglycemia-area under curve 0.89 +/- 0.54, mean amplitude of glycemic 
      excursions (MAGE) (5.13 +/- 2.23) mmol/L, M-value (18.93 +/- 11.43) mmol/L and 
      insulin dosage (42.11 +/- 14.42) U/day of observation group were significantly 
      lower than in the control group (P < 0.05). Glucose excursions after meals and 
      the times (0.33 +/- 0.50)/day, the maintenance time (43.75 +/- 43.50)/min and low 
      glycemic index (LBGI) (0.005 +/- 0.002) mmol/L of hypoglycemia at night were also 
      significantly lower than in the control group, with statistically significant (P 
      < 0.05) differences. CONCLUSION: The blood glucose fluctuation was significantly 
      improved, with the decrease of insulin dosage while both glucose excursions and 
      hypoglycemia at night reduced in patients with type1 diabetes mellitus after the 
      acarbose treatment.We suggested that this program deserve further observation.
FAU - Ma, Yan-rong
AU  - Ma YR
AD  - Department of Endocrinology of Zhongnan Hospital of Wuhan University, Wuhan 
      430000, China.
FAU - Xu, Yan-cheng
AU  - Xu YC
FAU - Ge, Jia-pu
AU  - Ge JP
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhonghua Liu Xing Bing Xue Za Zhi
JT  - Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
JID - 8208604
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
RN  - T58MSI464G (Acarbose)
SB  - IM
MH  - Acarbose/*therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Blood Glucose/*metabolism
MH  - Diabetes Mellitus, Type 1/blood/*drug therapy
MH  - Female
MH  - Humans
MH  - Insulin/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2012/09/13 06:00
MHDA- 2014/04/18 06:00
CRDT- 2012/09/13 06:00
PHST- 2012/09/13 06:00 [entrez]
PHST- 2012/09/13 06:00 [pubmed]
PHST- 2014/04/18 06:00 [medline]
PST - ppublish
SO  - Zhonghua Liu Xing Bing Xue Za Zhi. 2012 Aug;33(8):854-6.